SCHEDULE: Forte Biosciences Schedule 13G Filing Update

Forte Biosciences, Inc. has filed an amendment to its Schedule 13G, reporting changes in beneficial ownership.

Summary

• This filing is an amendment to a Schedule 13G for Forte Biosciences, Inc.
• The filing details ownership information for Federated Hermes, Inc., Voting Shares Irrevocable Trust, Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue.
• All reporting persons have reported 0.00 shares beneficially owned, representing 0% of the class of securities.
• The filing indicates that the reporting persons are filing as parent holding companies or control persons, acting as investment advisers or trustees.
• The event date requiring this filing is August 31, 2026.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a neutral filing, primarily administrative in nature, with no new financial or strategic information presented.

Negatives

• All reporting persons have declared 0.00 shares beneficially owned, indicating no significant stake or change in holdings.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Management Comments

• Federated Hermes, Inc. is filing as a parent holding company, acting as investment adviser to registered investment companies and separate accounts that owned shares of common stock in Forte Biosciences, Inc.
• The Trustees have joined in filing this Schedule 13G because of the collective voting control that they exercise over the Parent.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are typically made by institutional investors or other entities that acquire beneficial ownership of more than 5% of a class of a company's registered equity securities. This filing, however, reports 0% ownership, suggesting a change or confirmation of no significant holdings by these entities.

Key Dates

Keywords

Schedule 13G, Forte Biosciences, Beneficial Ownership, Federated Hermes, Investment Adviser, Trustee